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Abstract 24 
The performance of the Xpert-MRSA PCR assay on pooled nose, groin, and throat swabs (3 25 
nylon flocked eSwabs into one tube) was compared to culture by analyzing 5546 samples. 26 
Sensitivity (0.78, 95%CI 0.73-0.82) and specificity (0. 99, 95%CI 0.98-0.99) were similar to 27 
results from published studies on separated nose or other specimens. Thus, the performance of 28 
Xpert-MRSA was not affected by pooling the three specimens into one assay, allowing a 29 
higher detection rate without increasing laboratory costs, as compared to nose samples alone. 30 
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Introduction 33 
Rapid and accurate detection of methicillin-resistant Staphylococcus aureus (MRSA) carriers 34 
helps reducing the risk of transmission to other patients. Rapid PCR-based methods enable to 35 
confirm or refute MRSA carriage in patients within two hours. Most of them were evaluated 36 
with nose specimens, whereas studies showed that multiple site sampling increase the 37 
sensitivity of MRSA detection [1-6]. 38 
The high price of commercially available rapid PCR tests for MRSA screening leads some 39 
laboratories to pool specimens of the same patient into one single assay [7], whereas others 40 
consider that these tests are not cost-effective [8]. Some studies addressed the effect of 41 
pooling nose and groin samples on test's performances [9, 10]. As both throat and groin are 42 
additional important site for MRSA detection [1, 5, 6], validation of Xpert-MRSA (Cepheid, 43 
Sunnyvale, USA) done on these three swabs was required. Most of these studies were done 44 
using the Cepheid collection device (Venturi Transystem; Copan, Brescia, Italy). The new 45 
eSwab device (Copan) is increasingly used because it is suitable for automated inoculation of 46 
agar plates, and is more sensitive to recover bacteria by culture, including MRSA screening 47 
[11-13]. Therefore, we aimed at assessing the performance (sensitivity, specificity, positive 48 
[PPV] and negative [NPP] predictive values) of Xpert-MRSA on pooled nose, throat, and 49 
groin specimens using eSwabs and culture as the gold standard. 50 
Material and Methods 51 
Screening samples (nose, groin and throat) were performed using the eSwab MRSA system 52 
(Copan). This collecting device is composed of a screw-cap tube filled with 1ml of Amies 53 
liquid and three swabs with flocked nylon fiber tip. Xpert-MRSA tests were performed 54 
according to manufacturer instructions, except that 100 L of the Amies liquid were used to 55 
perform the analysis. For culture, about 250 l of the Amies liquid were inoculated into m-56 
Staphylococcus broth (Difco, Basel, Switzerland), incubated overnight at 35°C. The broth 57 
was then inoculated onto chromogenic MRSA-Select agar (Biorad, Marne-la-Coquette, 58 
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France), incubated overnight at 35°C [14]. Sensitivity, specificity, PPV and NPV of Xpert-59 
MRSA, and their 95% confidence intervals, were calculated using the online calculator 60 
(http://faculty.vassar.edu/lowry/clin1.html). 61 
Results 62 
To assess the effect of pooling samples on rapid MRSA detection, we performed a 63 
preliminary investigation. Nose, groin and throat sites of 50 known MRSA carriers were 64 
swabbed first with separate eSwab devices (3 swabs in 3 separated tubes) and then with the 65 
eSwab MRSA system (3 swabs in one tube). Each specimen (tube) was analyzed by Xpert-66 
MRSA and culture. In addition, 150 l of nose, groin and throat separate samples were pooled 67 
at the laboratory before analysis. With the Xpert-MRSA test, separate analyses of nose, throat 68 
and groin yielded a total of 38 (76%) positive patients (Table 1), whereas when specimens 69 
were pooled, either by the nurses or at the laboratory, 34 (68%) and 35 (70%) patients were 70 
positive, respectively. Similar results were obtained with culture (Table 1). Thus, a loss in 71 
sensitivity of only 6% could be attributed to pooling. This reduction is largely compensated 72 
by the benefit of adding throat and groin samples, which overall increase the detection from 73 
52% and 54% to 76% and 78% for Xpert-MRSA and culture, respectively (Table 1). These 74 
results are similar to data reported in a larger study [1]. Sensitivities of Xpert-MRSA 75 
compared to culture as gold standard were not significantly different regarding the site of 76 
sampling or the pooling protocol (harvested in one tube by nurses or pooled at the laboratory) 77 
(Table 1) and were similar to the 86% sensitivity (95%CI 0.81-0.91) reported by the  78 
manufacturer. Thus, we choosed the eSwab MRSA system (3 swabs in one tube) for a larger 79 
evaluation. 80 
From July 2011 to May 2012, 5555 pooled samples (nose, groin and throat) were analyzed 81 
both by Xpert-MRSA and culture. Only 9 samples (0.16%) showed invalid results after being 82 
tested twice by Xpert-MRSA, and were excluded from the analysis. Considering culture as 83 
the gold standard, we observed among the 5546 remaining samples a total of 65 false negative 84 
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and 68 false positive results. Thus, the sensitivity of Xpert-MRSA was 0.78 (95%CI 0.72-85 
0.82), the specificity 0.99 (95%CI 0.98-0.99), the PPV 0.77 (95%CI 0.72-0.82), and the NPV 86 
0.99 (95%CI 0.98-0.99). These results are similar to previously reported study on Xpert-87 
MRSA [7, 10, 15-20]. 88 
Discussion 89 
Whether the Xpert-MRSA test is adequate to detect MRSA carriers is an important question. 90 
Among the 335 new MRSA carriers identified during this period, 37 (11%) would have been 91 
missed if culture would not have been performed, a ratio similar to a previous report [21]. 92 
There are several reasons for that. Some studies report the failure of Xpert-MRSA to detect 93 
strains harboring SCCmec variants [19, 22] or the newly described mecC [23]. In our study, 94 
among 65 false negatives, at least 55 (85%) were due to MRSA strains belonging to four 95 
predominant clones in our area (data not shown), which are usually correctly identified by 96 
Xpert-MRSA (ST45-IV, ST5-II, ST228-I, and ST8-VI; [24]). This indicates that the majority 97 
of false negatives were not due to SCCmec variants. Another explanation could be the lower 98 
performance of Xpert-MRSA compared to culture. This hypothesis is supported by a study 99 
reporting that the limit of detection of enrichment culture was about 15 time lower (40 100 
CFU/ml) than Xpert-MRSA PCR (610 CFU/ml) [17]. 101 
In this work, we also observed 68 false positives. Among these, 33 (49%) were due to the 102 
presence of methicillin-sensitive S.aureus strains that did not possess the mecA, but still 103 
possess part of the SCCmec and the chromosome targeted by Xpert-MRSA (detected 104 
according to a previously described protocol [21]). False positives could also be due to the 105 
presence of dead MRSA cells in former carriers. 106 
In conclusion, the high NPV (99%) of Xpert-MRSA that we observed when pooling nose, 107 
throat and groin samples supports the use of this procedure to detect MRSA and to rapidly 108 
stop or avoid unnecessary preemptive isolation measures. By pooling these samples we 109 
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increased the efficiency of MRSA screening without increasing the laboratory costs. 110 
Moreover, by using the eSwab system, automated inoculation is possible. 111 
 112 
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 214 
Table 1. Number of positive results and sensitivity of Xpert MRSA compared to culture on 215 
pooled or non pooled samples of nose groin and throat among 50 known MRSA carriers. 216 
 No of positives by 
Xpert MRSA 
No of positives 
by culture 
Sensitivity 
(95% CI) 
Nose 26 (52%) 27 (54%) 0.89 (0.70-0.97) 
Throat 21 (42%) 27 (54%) 0.78 (0.57-0.90) 
Groin 31 (62%) 34 (68%) 0.88 (0.72-0.96) 
Pooled results from separated 
analysis of the 3 sites* 
38 (76%) 39 (78%) 0.92 (0.78-0.98) 
Pooled from 3 separated eSwabs 
by lab technicians 
35 (70%) 36 (72%) 0.86 (0.70-0.95) 
Swabs pooled within one eSwab 
tube by the nurses 
34 (68%) 36 (72%) 0.86 (0.70-0.95) 
*, if one or more sites were positive, the pooled result was considered positive. It was 217 
considered negative only when the 3 sites were negative. 218 
 219 
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